Biotech

An early-stage biotech was looking to develop a therapeutic strategy and clinical development plan for its proprietary research and development platform. We supported the organization by analysing the value at stake for indications in three therapeutic areas, assessed the trade-off between technical feasibility and scientific fitness, and evaluated its competitive landscape and business-model options. As a result, the organization defined a clinical development strategy and business model to operationalize across three therapeutic areas with the most opportunity.

An early-stage oncology focused biotech was planning for public listing and we supported them in crafting the IPO equity story. We synthesized key value drivers by assessing portfolio and company capabilities against peer company sets, articulated the portfolio narrative by considering scientific differentiations, competitive positioning, and commercial value, and cocreated the investment-equity story with the biotech executives tailored toward the target investors.

A cross-border biotech with a broad portfolio of transformative innovations to launch in an Asian market wanted to define a franchise strategy to guide future portfolios and commercial-operation building. We supported the company by benchmarking against successful franchises in respective therapeutic areas to extrapolate key success factors and synthesized forward-looking requirements on the franchise build to formulate the franchise strategy anchoring on company competitive strength. We also defined a roadmap to execute the key franchise strategy recommendations to position the biotech as a future leader by 2030.

A clinical-stage biotech with a unique platform and a lead asset in immunology aspired to find a codevelopment partner to accelerate and broaden the pipeline. We supported the company over more than a year in a partnership. We cocreated the equity story for a larger funding round, refined the clinical-trial design of the lead asset, outlined the go-to-market model, detailed the value proposition, and supported partnering negotiations, which resulted in the biotech reaching a prosperous, successful deal conclusion.